UCB SA (UCB) is a biopharmaceutical company that is engaged in the discovery and development of novel medicines and solutions for the treatment of various severe diseases. It strives to develop products for the treatment of neurology and immunology related conditions. The company's marketed products include Cimzia for ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, psoriatic arthritis, non-radiographic axial spondyloarthritis and rheumatoid arthritis; Neupro for Parkinson's disease and restless legs syndrome; Evenity for osteoporosis, and Vimpat, Keppra and Briviact for epilepsy. The company operates through subsidiaries in the US, Japan, China, Germany, Italy, Spain, France, the UK, Ireland, Belgium, Brazil, Russia, India, Mexico, Turkey and other countries. UCB is headquartered in Brussels, Brussels-Capital Region, Belgium.

Headquarters Belgium

Address Allee De La Recherche, 60, Anderlecht, 1070


Telephone 32 2 5599999

No of Employees 8,561

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange UCB (EBR)

Revenue (2020) $6.8B 8% (2020 vs 2019)

EPS XXX

Net Income (2020) XXX 44.7% (2020 vs 2019)

Market Cap* $13.6B

Net Profit Margin (2020) XXX 33.9% (2020 vs 2019)

* As of and is in US$

Access premium data and analytics for UCB SA

830+

Clinical Trials

Determine UCB SA go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

330+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for UCB SA’s relevant decision makers and contact details.

270+

Catalyst Calendar

Proactively evaluate UCB SA’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

160+

Marketed Drugs

Understand UCB SA’s commercialized product portfolio to stay one step ahead of the market.

90+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

90+

Pipeline Drugs

Identify which of UCB SA’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

30+

Sales & Consensus Forecasts

Understand the current and future drug revenue for UCB SA and assess market opportunity for new entrants with patient population 8-year forecasts.

20+

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

1

Investigators

Review investigator profiles and find information on trial contacts across UCB SA, including performance indicators like number of completed trials, and linked attributes such as rehiring statistics.

130+

Install Base

Install Base provides a holistic and a granular view of the IT product/service deployments from leading vendors. Explore IT infrastructure categories, solution and product/service areas deployed by a prospect.

80+

Medical Clinical Trials

A database of clinical trials planned, currently ongoing, completed, suspended, withdrawn, and terminated in countries around the world.

50+

Consumer Market Data Insights

Gain insights from product sales across markets, product categories and channels. Get intelligence on market shares, retail sales footprint, market position and strength for consumer segments and geographies.

8

Medical Marketed Products

A database of medical devices currently for sale around the world. Devices that have been approved by a regulatory authority are included.

5

Medical Pipeline Products

A database of medical devices that are in the process to get approved for sale around the world. Devices that are in development, through to those in the approval process are included.

3

IT Services Contracts

Improve competitive bidding with insights into all publicly disclosed IT services contracts for UCB SA (including IT outsourcing, business process outsourcing, systems integration & consulting and more).

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on UCB SA’s likely spend across technology areas enabling you to understand the digital strategy.

Subscribe to Company Analytics & gain access to premium industry data & analytics Subscribe to Company Analytics & gain access to premium industry data & analytics Start Here

Products and Services

Products Brands
Product Indications: Cimzia
Neurology: Vimpat
Epilepsy Keppra
XXX XXX
XXX XXX
XXX XXX
Subscribe to Company Analytics for access to more products & services data Subscribe to Company Analytics for access to more products & services data Learn More

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2022 Contracts/Agreements In June, the company announced a drug discovery research collaboration with Roswell Biotechnologies to evaluate the Roswell Molecular Electronics Platform (Roswell ME Platform) and Roswell Molecular Electronics Chip.
2022 Regulatory Approval In March, the company secured FDA approval for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome in patients two years of age and older.
2022 Contracts/Agreements In March, the company entered into a partnership with BrightInsight, Inc to develop and bring to market a digital disease management solution for patients with rare diseases.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Get Started
Image for loader

Competitor Comparison

Key Parameters UCB SA Johnson & Johnson Novartis AG GSK plc AstraZeneca Plc
Headquarters Belgium United States of America Switzerland United Kingdom United Kingdom
City Anderlecht New Brunswick Basel Brentford Cambridge
State/Province - New Jersey - - Cambridgeshire
No. of Employees 8,561 141,700 108,000 90,096 83,100
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Stefan Oschmann Chairman Executive Board 2021 65
Jean-Christophe Tellier Chief Executive Officer Senior Management 2014 63
Sandrine Dufour Chief Financial Officer; Executive Vice President Senior Management 2020 56
Iris Low-Friedrich, M.D. Chief Medical Officer; Executive Vice President - Global Projects and Development Senior Management 2008 61
Dhavalkumar Patel Chief Scientific Officer; Executive Vice President Senior Management 2017 61
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Gain more insight into company management & employee structure with Company Analytics Gain more insight into company management & employee structure with Company Analytics Subscribe
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer